Home›Research›Compare›CGRP vs TB-500
Peptide ComparisonCGRP vs TB-500
Both are Tissue Repair peptides.
CGRP
Calcitonin Gene-Related Peptide
Half-life: ~3.6 min / ~13.6 min (biphasic; sheep)
2 providers listed
TB-500
thymosin beta 4
Half-life: 5–7 days
402 providers listed
CGRP is FDA-approved, while TB-500 is banned from compounding — the clearest structural difference between them.
CGRP
Evidence
Half-life
~3.6 min / ~13.6 min (biphasic; sheep)
TB-500
Evidence
Half-life
5–7 days
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | CGRP |
| Further along in FDA review | CGRP |
| Less frequent dosing (longer half-life) | TB-500 |
| More provider options (2 vs 402) | TB-500 |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
CGRP
TB-500
CGRP
Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous prevent…
A Controlled Trial of Erenumab for Episodic Migraine
Three-year real-world effectiveness, treatment persistence, and planned discontinuation of anti-calcitonin ge…
Astrocyte-Targeted Biomarkers for Calcitonin Gene-Related Peptide-Related Neurovascular Disorders: Insights f…
+10 more
TB-500
Tβ4-Ac-SDKP pathway: Any relevance for the cardiovascular system?
Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis
Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db…
About CGRP
Binds CLR/RAMP1 receptor complex. Causes vasodilation via cAMP/PKA/nitric oxide pathway. Modulates nociceptive signaling in the trigeminal system. Promotes bone healing and has anti-inflammatory effects in peripheral tissues.
About TB-500
TB-500 exerts its effects primarily through promotion of actin polymerisation and cell migration. It upregulates the expression of beta-4 thymosin, which facilitates endothelial and muscle satellite cell movement to injury sites. Unlike BPC-157, TB-500 appears to act via a more systemic mechanism rather than locally at the administration site.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
CGRP
No structured contraindication profile is available for this compound yet. This compound is FDA-approved — consult the official prescribing information or a qualified clinician.
Under clinical review
Being verified by our medical team before we display monitoring guidance for this peptide.
TB-500
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
global — WADA
TB-500 / thymosin β4 is on the WADA Prohibited List at all times (S2.3, Growth Factors), effective 2018. It has no FDA approval and no human RCT evidence for injectable use.
sourceTB-500
BPC-157
Research suggests BPC-157 and TB-500 may produce enhanced tissue repair effects when combined. BPC-157 is studied for angiogenesis and gut-protective properties, while TB-500 promotes actin assembly and cell migration — complementary mechanisms in healing models.
CGRP
Not enough vendor pricing yet.
TB-500
Where to source these peptides
CGRP
2 listed
Browse directory →
Providers offeringTB-500
402 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Tissue Repair Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 20, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). CGRP vs TB-500 — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/cgrp/tb-500